Table 1.
Demographic and clinical characteristics of adult PLWHIV by viral detectability at AIDC of UTH, Lusaka, Zambia (n = 7,281).
| Characteristic | Detectable | Undetectable | Overall |
|---|---|---|---|
| VL≥200 copies/ml | VL<200 copies/ml | ||
| % ( n ) | % ( n ) | ( n ) | |
| 9.0% (653) | 91.0% (6,628) | n = 7,281 | |
| Sex | |||
| Male | 8.9% (255) | 91.1% (2,602) | 2,857 |
| Female | 9.0% (398) | 90.0% (4,026) | 4,424 |
| Age in years Mean (SD) | 40.7 (13.1) | 44.2 (12.7) | 43.9 (12.8) |
| CD4 cell count at ART initiation | |||
| ≥200 cells/mm3 | 7.4% (478) | 92.6% (5,942) | 6,420 |
| < 200 cells/mm3 | 20.3% (175) | 79.7% (686) | 861 |
| ART start year | |||
| < 2019 | 7.9% (539) | 92.1% (6,312) | 6,851 |
| 2019+ | 26.5% (114) | 73.5% (316) | 430 |
| Current type of ART regimen | |||
| Dolutegravir-based (TLD/TafED) | 7.7% (439) | 92.3% (5,275) | 5,714 |
| Efavirenz-based (TLE/Atripla) | 13.7% (214) | 86.3% (1,353) | 1,567 |
| Dispensing interval | |||
| 1 month | 17.6% (105) | 82.4% (492) | 597 |
| 3 months | 11.0% (63) | 89.0% (508) | 571 |
| 6 months | 7.9% (485) | 92.1% (5,628) | 6,113 |
| WHO staging at ART initiation | |||
| WHO HIV clinical stage 1 | 8.8% (414) | 91.2% (4,270) | 4,684 |
| WHO HIV clinical stage 2 | 11.9% (65) | 88.1% (479) | 544 |
| WHO HIV clinical stage 3 | 8.8% (117) | 91.2% (1,207) | 1,324 |
| WHO HIV clinical stage 4 | 7.8% (57) | 92.2% (672) | 729 |
1. Overall mean age in years is 43.9 (±12.8), among those with detectable viral load, 40.7 (±13.1), and for those with undetectable viral load, 44.2 (±12.7). 2. Overall median CD4 cell count at ART initiation in cells/mm3 (IQR) is 461 (306-635), among those with detectable viral load, 343 (190-541), and for those with an undetectable viral load.